First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.
Department of Minimally Invasive Comprehensive Treatment of Cancer, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, People's Republic of China.
Sci Rep. 2023 Feb 1;13(1):1819. doi: 10.1038/s41598-023-29065-2.
Organoids are a new type of 3D model for tumor research, which makes up for the shortcomings of cell lines and xenograft models, and promotes the development of personalized precision medicine. Long-term culture, expansion and storage of organoids provide the necessary conditions for the establishment of biobanks. Biobanks standardize the collection and preservation of normal or pathological specimens, as well as related clinical information. The tumor organoid biobank has a good quality control system, which is conducive to the clinical transformation and large-scale application of tumor organoids, such as disease modeling, new drug development and high-throughput drug screening. This article summarized the common tumor types of patient-derived organoid (PDO) biobanks and the necessary information for biobank construction, such as the number of organoids, morphology, success rate of culture and resuscitation, pathological types. In our results, we found that patient-derived tumor organoid (PDTO) biobanks were being established more and more, with the Netherlands, the United States, and China establishing the most. Biobanks of colorectal, pancreas, breast, glioma, and bladder cancers were established more, which reflected the relative maturity of culture techniques for these tumors. In addition, we provided insights on the precautions and future development direction of PDTO biobank building.
类器官是一种新型的肿瘤研究 3D 模型，弥补了细胞系和异种移植模型的不足，促进了个性化精准医学的发展。类器官的长期培养、扩增和储存为生物库的建立提供了必要条件。生物库规范了正常或病理标本的采集和保存，以及相关的临床信息。肿瘤类器官生物库具有良好的质量控制系统，有利于肿瘤类器官的临床转化和大规模应用，如疾病建模、新药开发和高通量药物筛选。本文总结了常见的患者来源的类器官（PDO）生物库的肿瘤类型和生物库建设所必需的信息，如类器官的数量、形态、培养和复苏成功率、病理类型。我们的研究结果表明，越来越多的患者来源的肿瘤类器官（PDTO）生物库正在建立，荷兰、美国和中国建立的生物库最多。结直肠、胰腺、乳腺、神经胶质瘤和膀胱癌的生物库建立得更多，这反映了这些肿瘤培养技术的相对成熟。此外，我们还就 PDTO 生物库建设的注意事项和未来发展方向提供了一些见解。
